



Closed-loop stimulation in periods with less epileptiform activity drives improved epilepsy outcomes

✉ Daria Nesterovich Anderson,^{1,2,3} ✉ Chantel M. Charlebois,^{4,5} ✉ Elliot H. Smith,¹ Tyler S. Davis,¹ Angela Y. Peters,⁶ Blake J. Newman,⁶ Amir M. Arain,⁶ Karen S. Wilcox,² Christopher R. Butson^{7,8,9,10} and ✉ John D. Rolston^{4,11}

In patients with drug-resistant epilepsy, electrical stimulation of the brain in response to epileptiform activity can make seizures less frequent and debilitating. This therapy, known as closed-loop responsive neurostimulation (RNS), aims to directly halt seizure activity via targeted stimulation of a burgeoning seizure. Rather than immediately stopping seizures as they start, many RNS implants produce slower, long-lasting changes in brain dynamics that better predict clinical outcomes. Here we hypothesize that stimulation during brain states with less epileptiform activity drives long-term changes that restore healthy brain networks. To test this, we quantified stimulation episodes during low- and high-risk brain states—that is, stimulation during periods with a lower or higher risk of generating epileptiform activity—in a cohort of 40 patients treated with RNS.

More frequent stimulation in tonic low-risk states and out of rhythmic high-risk states predicted seizure reduction. Additionally, stimulation events were more likely to be phase-locked to prolonged episodes of abnormal activity for intermediate and poor responders when compared to super-responders, consistent with the hypothesis that improved outcomes are driven by stimulation during low-risk states.

These results support the hypothesis that stimulation during low-risk periods might underlie the mechanisms of RNS, suggesting a relationship between temporal patterns of neuromodulation and plasticity that facilitates long-term seizure reduction.

1 Department of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA

2 Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA

3 School of Biomedical Engineering, Faculty of Engineering, The University of Sydney, Darlington, NSW 2008, Australia

4 Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA

5 Scientific Computing and Imaging Institute, University of Utah, Salt Lake City, UT 84112, USA

6 Department of Neurology, University of Utah, Salt Lake City, UT 84132, USA

7 Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA

8 Department of Neurology, University of Florida, Gainesville, FL 32611, USA

9 Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA

10 Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA

11 Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

Correspondence to: John D. Rolston, MD, PhD

Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School

60 Fenwood Rd, BTM 4th Floor

Boston, MA 02115, USA

E-mail: jrolston@bwh.harvard.edu

Keywords: responsive neurostimulation; neuromodulation; brain states; closed-loop stimulation; epilepsy

Introduction

Closed-loop responsive neurostimulation (RNS) is a US Food and Drug Administration (FDA)-approved therapy for treatment-resistant epilepsy, used when resection or lesioning is not an option. While true seizure freedom is rare, seizure reduction is common with RNS and improves over time. The initial clinical trial for the RNS system reported a 53% median decrease in seizure frequency and 12.9% seizure-free period of at least 1 year, at 2 years,^{1,2} while 9-year outcomes boast 75% median decrease in seizure frequency and 18.4% seizure freedom rates for at least a 1-year period.³ RNS not only has an acute effect via a reduction in spectral power post-stimulation,⁴ but continued therapy leads to long-term improvements.³

Improved clinical outcomes have correlated with various features of neural signals recorded on RNS. For instance, previously reported ‘indirect effects’ of stimulation, such as spontaneous ictal inhibition or altered frequency dynamics during seizures, correlated with better clinical outcomes while acute, direct effects of stimulation did not correlate with outcomes.⁵ Furthermore, a cohort of super-responder neuromodulation patients (>90% improvement) experienced functional network reorganization while poor responders (<50% improvement) did not experience these network changes.⁶ Taken together, these results suggest that network reorganization might drive improved clinical outcomes. Determining the factors that enable plastic, functional changes over time from those that do not will be critical for understanding and improving response to neuromodulation.

Based on evidence that synapses may already be saturated after the seizure event, thereby impairing long-term plasticity after a seizure,^{7–9} it is unlikely that long-lasting network changes occur from stimulation occurring during seizures. While stimulation during a seizure might act through acute desynchronization to arrest a seizure,¹⁰ we hypothesized that stimulation occurring during periods of relative ictal quiescence leads to long-lasting functional network changes that are correlated with improved outcomes.

To test this hypothesis, we divided patient stimulation into periods with higher risk (high-risk epoch) or lower risk (low-risk epoch) of generating seizures and correlated the respective stimulation to clinical outcomes. Determining whether stimulation is in a high- or low-risk epoch may be estimated based on stimulation counts and repetitive detections, known as long episodes, collected from each patients’ intracranial device.¹¹ We found early biomarkers of RNS efficacy, namely that stimulation in low-risk epochs promoted improved clinical outcomes.

Materials and methods

Study design

This study aimed to quantify stimulation patterns and the temporal dynamics of low- and high-risk brain states in a cohort of 40 patients at the University of Utah who were treated with the NeuroPace RNS system. All cases were performed at the University of Utah hospital from 2015–2021 and a retrospective analysis of this cohort was approved by the University of Utah Institutional Review Board. Patients were included in this study if stimulation was enabled and had a baseline seizure frequency and follow-up seizure frequency reported by a board-certified epileptologist at last follow-up at least 180 days after stimulation had been enabled. A full table containing summaries of patient demographic information and lead placement can be found in

[Supplementary Table 1](#). No patients with psychogenic seizures were included in this study to ensure accurate reporting of the baseline seizure rate and seizure rate after follow-up.

Measuring clinical outcome

All clinical outcomes and monthly seizure frequency rates were recorded by board-certified epileptologists during clinical interviews. Seizure reduction was quantified as a percentage, calculated by subtracting the follow-up monthly seizure frequency from the monthly baseline seizure frequency, divided by baseline seizure frequency (Eq. 1).

$$\% \text{ SeizureReduction} = 100$$

$$\times \frac{\text{SeizureFreq}_{\text{Baseline}} - \text{SeizureFreq}_{\text{Follow-up}}}{\text{SeizureFreq}_{\text{Baseline}}} \quad (1)$$

A 100% seizure reduction value indicates seizure freedom at follow-up, while a 0% seizure reduction indicates no change from baseline at follow-up. A negative seizure reduction value indicates worsening seizure frequency and only occurred for one patient in this cohort. Patients were categorized into three groups based on their seizure reduction values: super-responders (>90% reduction, $n = 10$), intermediate responders ($\geq 50\%$ reduction and $\leq 90\%$ reduction, $n = 19$) and poor responders (<50% reduction, $n = 11$) (Fig. 1A). In analyses where outcomes were not analysed on a continuum, intermediate and poor responders were grouped together ($n = 30$) to be compared to super-responders ($n = 10$). This grouping was done to capture all potential patient variability and identify major differences from patients with subpar outcomes to those with ideal outcomes from therapy.

Calculation of daily risk periods

Calculation of low-risk periods was motivated by prior work from Chiang et al.,¹¹ who defined optimal stimulation parameters based on high- and low-risk states using histogram data extracted from the RNS system. We used long episode counts and saturations as exported from the RNS system to determine risk states in this study. Depicted in Fig. 1D, daily long episodes counts were retrieved and convolved with a normalized kernel of [1/4, 1/2, 1/4] days to ensure that counts from the previous day and following day factored into risk assessment for each day. To determine whether a period was high risk, the average number of convolved long episodes from the previous week was used as a threshold. If the daily risk amplitude was greater than the prior 7-day threshold, then the day was considered high-risk, while if the value was less than or equal to the prior 7-day threshold, then the day was considered low-risk. We used a 7-day window to define a moving risk metric rather than taking the average over the entire time series to account for instances when programming settings were changed, potentially altering the number of long episodes detected. For patients who did not reliably sync their device and have gaps in their histogram data, we followed established methods^{12,13} to fill in the gaps in the histogram data when fewer than 12 h of histogram data were logged in one day. An example of this method can be found in [Supplementary Fig. 5](#).

Circadian and multidien rhythms

Circadian and multidien rhythms were calculated from the patient histogram data using the number of detections across all RNS




Figure 1 Patient cohort summary and determination of high- and low-risk epochs. (A) Summary of patients incorporated into the study. Forty patients were included in the study: 10 super-responders, 19 intermediate responders and 11 poor responders. (B) The responsive neurostimulation (RNS) system is effective at reducing seizure frequency (one sample t-test; $P < 0.0001$) with a median seizure reduction of 64.6% (lower quartile: 37.1%, upper quartile: 90.8%). (C) We provide a theoretical example of a high-risk epoch stimulation event we hypothesize will not lead to long-term network changes versus low-risk epoch stimulation that we hypothesize leads to long-term network changes. (D) Demonstration of risk period calculation for a 6-month period in an example patient. Long episode counts are extracted from the RNS system and convolved with a $[1/4, 1/2, 1/4]$ day kernel window to calculate risk amplitude. A day is considered high risk if the calculated daily risk is greater than the previous 7-day average of risk amplitudes. Example electrocortigraphy (ECoG) traces from periods of high risk and low risk are shown to parallel our hypothesis in (C). Yellow bars indicate deployed stimulation.

channels following similar methods, as described in previous literature.^{12–14} The time series data were z-scored within each programming epoch to accommodate changes to detection settings during programming sessions. Wavelet transforms were produced for each patient by a continuous wavelet transform (Morlet) on the z-scored detection counts across all therapy from a periodic range of 3 h to 45 days over 91 periodic bins. The CircStat toolbox was used to calculate peak hour (mean angle) and phase-locking value (mean resultant vector) of detections on a 24-h cycle to determine whether the phase-locking value, the stability of the peak hour, and time of peak detection correlated to seizure reduction. We weighted the instantaneous phase from the continuous wavelet transform using the z-scored detections that occurred within each hour bin, considering the possibility of multiple detections per hour.

To determine the extent of phase locking of long episodes on circadian and multidien rhythms across the cohort, the mean angle and mean resultant vector were calculated by measuring the entrainment of long episodes on the circadian and largest prominent multidien peak (≥ 48 h). Patients with long episodes occurring slower than 45-day periods ($n = 2$) were excluded from the multidien phase-locking analysis.

To determine the change in periodogram over the course of therapy, the first and last 90-day window since stimulation were used to calculate an average periodogram for each patient. The 90-day periodogram was calculated by averaging each periodic time band from the wavelet transforms produced by a continuous wavelet transform (Morlet) on the z-scored detection counts from

a periodic range of 3 h to 32 days. The instantaneous phase and power were calculated over 81 periodic bins and the wavelet transform was L1 normalized to avoid the attenuation of amplitude at shorter periodic cycles. Note that the periodic range was reduced from 45 days to 32 days in this analysis given the shorter time window of data. All periodograms per patient were confirmed to sum up to 1. To quantify changes in periodicity over time, the periodograms from the first 90 days of stimulation were compared to periodograms generated in the 90 days before the follow-up outcome collected for super-responders and intermediate/poor responders.

To quantify phase-locking of long episodes to stimulation, we repeated the analysis used with detections counts using stimulation episode counts instead across all therapy. We plotted circular histograms of the probability distribution function of mean angles of long episodes and stimulation episodes for all periodics ranging from 3 h to 45 days. Von Mises distributions were calculated using the CircStat toolbox¹⁵ for each responder group and visualized over the top of the circular histogram plots.

Statistics

All analyses and statistics were completed in MATLAB 2021b. Unpaired statistical tests used a Student's t-test and paired statistics tests used two-sample t-tests. For data following a circular distribution, we used the CircStat toolbox, a circular statistics toolbox written for MATLAB,¹⁵ to determine correlation and significance. Additionally, circular two-sample Kuiper tests were used from the CircStat toolbox to test whether phase-locking distributions were




Figure 2 Seizure reduction is not significantly correlated with baseline seizure frequency, baseline detections or stimulation counts. (A) Factors that can predict outcomes to neuromodulation have the most benefit if used earlier in therapy. (B) There is no correlation between baseline seizure rate and outcome (Pearson's correlation; $P = 0.98$). (C) Prior to stimulation onset, in the baseline period, long episode counts are significantly correlated with monthly baseline seizures, indicating that long episodes correspond to baseline seizure rates (Pearson's correlation; $r = 0.399$, $R^2 = 0.159$, $P = 0.011$). (D) However, these baseline long episodes are not significantly correlated with seizure reduction (Pearson's correlation; $P = 0.30$). (E) Baseline detections are additionally not correlated with monthly baseline seizures (Pearson's correlation; $P = 0.22$). (F) Similarly, these baseline detections are not significantly correlated with seizure reduction (Pearson's correlation; $P = 0.62$). (G) Daily stimulation counts between super-responders and intermediate/poor responders are not significantly different either from the first 90 days of stimulation or over all stimulation time (two-sample t-test, $P = 0.50$; two-sample t-test, $P = 0.19$). (H) Tracking stimulation counts over time, intermediate/poor responders have an increase in stimulation over time (Pearson's correlation; $r = 0.772$, $R^2 = 0.596$, $P < 0.0001$).

from the same distribution. All shading in plots is defined by the mean \pm standard error.

Results

Outcomes and demographic variables were gathered for 40 patients implanted with RNS devices (Fig. 1A). Clinical outcomes were collected after patients had devices implanted for a median time of 860 days [lower quartile (LQ): 522 days, upper quartile (UQ): 1324 days]. Patients experienced a significant reduction in seizures with responsive neuromodulation therapy (Fig. 1B; one sample t-test; $P < 0.0001$). Median seizure reduction rates at follow-up were 64.6% (Fig. 1B; LQ: 37.1%, UQ: 90.8%). Using this patient cohort, we calculated how much time and how many stimulation episodes patients experienced according to methods described in Fig. 1D, and defined periods with below average epileptiform activity to be 'low risk', similar in concept to Chiang et al.¹¹

Failure to predict seizure reduction from standard metrics

We tested the hypothesis that an increased number of stimulation episodes delivered during periods of reduced epileptic activity is predictive of improved patient outcomes (Fig. 1C). The earlier it may be possible to determine predictors of patient outcomes, the more beneficial for patients (Fig. 2A). Baseline seizure frequency, known prior to

surgical intervention, was not able to predict subsequent seizure reduction (Fig. 2B). Additionally, patient age, age of epilepsy onset and epilepsy durations were not predictive of seizure reduction (Supplementary Fig. 1). Additionally, there was no significant relationship between the duration of therapy and patient outcome (Supplementary Fig. 2). Prior to stimulation being enabled, there was a median period of 36.5 days (LQ: 21 days, UQ 61 days) where the RNS system was implanted and detection protocols were similar across all patients, but stimulation was not yet turned on. We found that long episode counts, or prolonged and repeated detections, measured during this baseline period significantly correlated with monthly baseline seizure rate (Fig. 2C; Pearson's correlation, $r = 0.399$, $R^2 = 0.159$, $P = 0.011$), signifying that long episodes aptly quantify seizure burden. However, the number of baseline long episodes were not significantly correlated with seizure reduction and therefore were not able to predict outcomes early in therapy (Fig. 2D; Pearson's correlation, $P = 0.30$). Further, we neither saw a significant correlation in the number of baseline detections, linked to interictal epileptiform discharges,^{12–14} with monthly baseline seizure rates (Fig. 2E; Pearson's correlation, $P = 0.22$), nor a significant correlation between baseline detections with clinical outcomes (Fig. 2F; Pearson's correlation, $P = 0.61$). The number of stimulation episodes was initially similar between super-responders and intermediate/poor responders during the first 90 days (Fig. 2G), but the intermediate/poor responder groups experienced a steady increase in stimulation counts over the duration of their therapy (Fig. 2H; Pearson's

correlation, $r = 0.772$, $R^2 = 0.596$, $P < 0.0001$), likely due to intentional changes in detection parameters by the epileptologists.

Increased stimulation in low-risk periods predicts outcomes

We calculated time spent in low-risk periods for each patient for the first 90 days of stimulation according to methods described in Fig. 1D. From the onset of therapy, an increased ratio of time spent in low-risk states was correlated and predictive of seizure reduction (Fig. 3A; Pearson's correlation; $r = 0.477$, $R^2 = 0.227$, $P = 1.88 \times 10^{-3}$, leave-one-out cross validation: $P = 0.011$). Similarly, an increase in the ratio of stimulation episodes occurring during low-risk periods was correlated and predictive of seizure reduction (Fig. 3B; Pearson's correlation; $r = 0.456$, $R^2 = 0.208$, $P = 3.13 \times 10^{-3}$, leave-one-out cross validation: $P = 0.019$). Time spent in low-risk states significantly increased over time for intermediate/poor responders (Pearson's correlation, $P = 4.28 \times 10^{-4}$), which may correspond to long-term improvements reported in prior patient cohorts along multi-year time scales.³ However, even after nearly 2.5 years of stimulation, intermediate/poor responders still had a lower ratio of time in low-risk states on average than super-responders at any time point. We observed similar trends when analysing the three patient groups separately (super, intermediate and poor responders) (Supplementary Fig. 3).

We next asked how independent these two measures—the ratio of time in low-risk states and stimulation during low-risk states—were. That is, were patients who initially spend more time in low-risk states fated to do better or does stimulation during these low-risk states confer an added benefit? To dissect this relationship, we correlated the ratio of time in low-risk states (Fig. 3A) with low-risk stimulation (Fig. 3B). While these two metrics were highly correlated (Pearson's correlation; $r = 0.938$, $R^2 = 0.880$, $P = 4.65 \times 10^{-19}$), nearly all patients deviated from what would be expected if stimulation were delivered uniformly or by chance. As expected from a closed-loop device triggering stimulation upon the detection of epileptiform activity, most patients' stimulation episodes were biased to high-risk periods (Fig. 3D; one sample t-test; $P = 1.71 \times 10^{-4}$). Graphically, the solid blue line in Fig. 3D indicates a theoretical situation in which high-risk and low-risk stimulation episodes occur in identical proportions to the time spent in high- and low-risk states, a relationship that would be followed during open-loop stimulation (as in deep brain stimulation). Most patients treated with the RNS system fell below this line.

We next asked whether deviation from this 'unbiased' allocation of stimulation was correlated with seizure reduction. Indeed, having more high-risk stimulation episodes per seizure was correlated with diminished seizure reduction (Fig. 3E; Pearson's correlation; $r = -0.488$, $R^2 = 0.238$, $P = 1.4 \times 10^{-3}$). This analysis examines the number of extra high-risk stimulation episodes occurring per anticipated seizure, calculated by the monthly baseline seizure rate, versus if stimulation was applied equally across risk states, as observed in open-loop stimulation protocols. This finding supports the hypothesis that an increased low-risk stimulation may be beneficial for increased seizure reduction, and that excessive stimulation in high-risk epochs may contribute less to driving long-term neuromodulation-induced network changes.

Stronger circadian rhythms correspond to improved patient outcomes

Patients with epilepsy have been shown to have multiple nested rhythms of both interictal activity and seizures.¹² We therefore

quantified circadian rhythmicity in the number of detected epileptiform events to determine if patients with improved outcomes exhibited different circadian patterns. This question is centred around the hypothesis that if epileptiform activity was clustered in a narrower window of the day, the patient would spend more time daily in low-risk states. Our patient cohort had similar clusters to those identified by Baud *et al.*,¹² with the majority experiencing nightly peaks in detections, specifically between 5 a.m. and 9 a.m. (Fig. 4A). Dividing patients in three 8-h partitions, we found that 13 patients had a late evening clustering pattern (5 p.m. to 1 a.m.), 20 had an early morning clustering (1 a.m. to 9 a.m.) and seven patients had an afternoon clustering (9 a.m. to 5 p.m.). Of 40 patients, 13 had phase-locking values < 0.5 , which indicated weaker circadian patterns in their detections. The strength of the circadian phase-locking of epileptiform activity correlated with seizure reduction (Fig. 4B; Pearson's correlation; $r = 0.319$, $R^2 = 0.102$, $P = 0.045$) and may also explain why patients with improved responses spend more time in low-risk states daily.

Additionally, we found that a more stable peak hour was correlated to seizure reduction (Pearson's correlation; $r = -0.322$, $R^2 = 0.103$, $P = 0.043$) when we quantified the standard deviation of circadian peak hour for each patient in 45-day intervals throughout therapy (Fig. 4D). In the 8-h clusters, groups had average peak hours at 10.20 p.m., 4.50 a.m. and 1.50 p.m. (Fig. 4C) for late evening, early morning and afternoon clusters, respectively. Finally, we observed an insignificant trend that patients with circadian rhythms peaking shortly after midnight had improved outcomes (Fig. 4E; circular-linear correlation; $P = 0.142$).

Phase-locking of long episodes to patient rhythms

We additionally quantified the extent that long episodes or periods of repeated detections, which can be used as a surrogate for seizures (Fig. 2C), were phase-locked to each patient's unique circadian cycle and most prominent multidien cycle. In high agreement with Baud *et al.*,¹² we found that the majority of patients received stimulation between the rising phase and peak phase of daily detections (Fig. 5A). Similarly, for peak multidien rhythms, long episodes occurred between the rising and peak phases of the multidien rhythm (Fig. 5B). There was no correlation between the phase angle of long episodes on circadian (circular-linear correlation; $P = 0.91$) or multidien (circular-linear correlation; $P = 0.90$) cycles and seizure reduction.

To quantify how rhythms of epileptiform activity evolved over the course of stimulation, we calculated patient periodograms across periods spanning 3 h to 32 days from the first 90 days of stimulation therapy to the last 90 days of stimulation. Super-responder and intermediate/poor responder patients diverged significantly in the last 90 days of stimulation. Specifically, super-responder patients had increased power in short periods (≤ 24 h; Fig. 5C and D) (two-sample t-test, $P = 1.55 \times 10^{-3}$) while intermediate/poor responders had increased power in multidien periodics (≥ 48 h; Fig. 5C and D) (two-sample t-test, $P = 1.73 \times 10^{-3}$). We suspect a reduction in power during multidien periods, as observed in the super-responder group, indicates that seizures re-occurring on slower rhythms become less prominent and the respective increase in power in short periodics (≤ 24 h) may indicate a restoration of normal circadian rhythms.

We finally quantified the phase angle distributions for long episodes and stimulation episodes across the entire therapy duration for periods ranging from 3 h to 45 days (Fig. 5E). A greater concentration of bins at the peak indicates that most stimulation




Figure 3 Increased time spent in low-risk epochs and more stimulation occurring during low-risk epochs is predictive of clinical outcomes. (A) Patients with greater seizure reduction spend a greater amount of time in low-risk (LR) states (Pearson's correlation; $r = 0.477$, $R^2 = 0.227$, $P = 1.88 \times 10^{-3}$). This analysis holds up to leave-on-out cross-validation (Pearson's correlation; $P = 0.011$). Super-responder patients spend significantly more time in low-risk states than high-risk (HR) states in the first 3 months of stimulation (two-sample t-test, $P = 1.33 \times 10^{-3}$). (B) Patients with greater seizure reduction also experience more stimulation during low-risk epochs (Pearson's correlation; $r = 0.456$, $R^2 = 0.208$, $P = 3.13 \times 10^{-3}$). This analysis also holds up to leave one out cross-validation (Pearson's correlation; $P = 0.019$). Super-responder patients receive significantly more stimulation during low-risk states than high-risk states in the first 3 months of stimulation (two-sample t-test, $P = 1.59 \times 10^{-3}$). (C) Tracking time in low-risk states over the course of stimulation, we found that the ratio of time in low-risk states increases significantly over time for intermediate/poor responders (Pearson's correlation: $r = 0.620$, $R^2 = 0.385$, $P = 4.28 \times 10^{-4}$). Despite this, after nearly 2.5 years, intermediate/poor responders have not yet reached the ratio of time in low risk that super-responders began at. (D) A and B are highly correlated (Pearson's correlation; $r = 0.938$, $R^2 = 0.880$, $P = 4.65 \times 10^{-19}$). Compared to the solid blue line, which indicates a perfect balance between high-risk and low-risk stimulation, most RNS system patients have more high-risk stimulation than chance (one sample t-test; $P = 1.71 \times 10^{-4}$). (E) Having more high-risk stimulation episodes per seizure than chance correlates with poor clinical outcomes (Pearson's correlation; $r = 0.488$, $R^2 = 0.238$, $P = 1.4 \times 10^{-3}$). n.s. = not significant.

occurs in phase with long episodes, i.e. seizures. For intermediate and poor responders, there was a high level of phase-locking between long episodes and stimulation, as one would expect given the goal of closed-loop stimulation in response to epileptiform

activity (Fig. 5E). Interestingly, the distribution for super-responder patients was significantly different compared to both intermediate (two-sample Kuiper test; $P < 0.01$) and poor responders (two-sample Kuiper test; $P < 0.01$). This demonstrates that




Figure 4 Stronger circadian rhythms of detections correspond to improved patient outcomes. (A) Most patients had circadian patterns in detections that peak in the night-time. In three, 8-h partitions, 13 patients had a late evening clustering pattern (5 p.m. to 1 a.m.) with a peak hour at 10.20 p.m., 20 patients had an early morning clustering (1 a.m. to 9 a.m.) with a peak hour at 4.50 a.m. and seven patients had an afternoon clustering (9 a.m. to 5 p.m.) with a peak hour at 1.50 p.m. (B) A larger phase-locking value (PLV) signifies a greater extent detections were concentrated to a certain hour of the day. Patients with a larger PLV experienced improved seizure reduction (Pearson's correlation; $r = 0.319$, $R^2 = 0.102$, $P = 0.045$). (C) Individual traces of 8-h partition groups—in high agreement with Baud *et al.*¹² (D) A more stable peak hour throughout therapy was correlated to seizure reduction (Pearson's correlation; $r = -0.322$, $R^2 = 0.103$, $P = 0.043$). (E) The patient cohort exhibits a trend that patients with circadian rhythms with peaks shortly after midnight had improved outcomes (circular-linear correlation; $P = 0.142$). The weight peak hour was 8.00 a.m. for super-responders, 3.30 a.m. for intermediate responders and 10.07 p.m. for poor responders.

super-responders had increased instances of stimulation outside of the peak of long episode events compared to intermediate and poor responders.

Discussion

In this work, we present evidence that stimulation during brain states defined by higher or lower risk for seizures may be critical to improving patient outcomes with responsive neuromodulation for epilepsy. Our results contain several notable findings: (i) the amount of stimulation and ratio of time in low-risk states early in therapy is a predictor of outcomes, which increases steadily over time and matches reports of long-term improvements; (ii) super-responders had more narrow and consistent daily clustering of epileptiform activity than poor and intermediate responders, serving as an additional biomarker; and (iii) patients with improved outcomes had more stimulation episodes out of phase with long episodes, i.e. periods of repeated detections correlated with seizures. Together, these findings suggest that the presence of, and stimulation during, low-risk brain states both favour improved outcomes with closed-loop responsive neurostimulation.

State-dependent neurostimulation has been actively investigated for several neurological disorders, such as Parkinson's disease^{16,17} and Tourette syndrome.¹⁸ In the context of epilepsy, closed-loop intracranial neurostimulation targets epileptiform activity. The RNS system is often appreciated for targeting

stimulation with the goal of arresting the seizures when detected. However, most RNS system stimulation events happen in response to interictal epileptiform activity, which occurs hundreds to thousands of times daily compared to the seizures themselves, which occur at far lower rates. This makes the ratio of stimulation in the interictal versus ictal period based on baseline seizure rate more than 1000:1 for most patients (Supplementary Fig. 4). As we hypothesize in Fig. 1C, perhaps many of the functional changes observed in patients who respond to RNS system therapy are due to stimulation during 'low-risk' interictal states, rather than higher risk peri-ictal states.^{6,11}

To understand the motivation for this hypothesis, we return to basic principles of plasticity of neural connections. Seizures themselves are events that can facilitate future seizures through strengthening of excitatory connections¹⁹ and brain networks may undergo reorganization due to excess excitation.^{20,21} While the role of neuroplasticity is critical in the generation of epilepsy, harnessing neuroplasticity may be similarly important for neuro-modulation approaches to alter epileptic brain networks to restore healthy function. It has been reported that tissue taken from epileptic rodent models and human patients with epilepsy exhibits impaired synaptic plasticity.^{7,8} In human patients implanted with intracranial electrodes, memory tasks—which rely on plasticity—are impaired in the presence of interictal spiking.^{22–25} Taking this information into account, it seems plausible that the most opportune time to elicit lasting change to




Figure 5 Periodograms of super-responders and poor/intermediate responders diverge over time and stimulation of super-responders is less phase-locked to long episodes. (A) We found that most patients received stimulation between the rising phase and peak phase of daily detections. Seizure reduction did not significantly correlate with phase angle of long episodes on the circadian cycle (circular-linear correlation; $P = 0.91$). (B) For peak multidien rhythms, long episodes occurred between the rising and peak phase of the most prominent multidien rhythm (≥ 48 h). Seizure reduction did not significantly correlate with phase angle of long episodes on the circadian cycle (circular-linear correlation; $P = 0.90$). (C) Periodograms are not significantly different at the start of stimulation therapy between super-responders and intermediate/poor responders. (D) In the last 90 days of stimulation, super-responders experienced increased power in short periods (≤ 24 h) (two-sample t -test, $P = 1.55 \times 10^{-3}$) while intermediate/poor responders had increased power in multidien periodics (≥ 48 h) (two-sample t -test, $P = 1.73 \times 10^{-3}$). (E) Across all periods from 3 h to 45 days, there was a high level of phase-locking between long episodes and stimulation episodes in intermediate and poor responders. However, the distribution of stimulation episodes and long episodes between super-responders and both intermediate (two-sample Kuiper test; $P < 0.01$) and poor responders (two-sample Kuiper test; $P < 0.01$) were significantly different, indicating more stimulation occurred outside of high-risk long episodes in super-responders. Von Mises distributions for super-responders ($\mu: -1.39$ rad, $\kappa = 0.74$), for intermediate responders ($\mu: -0.36$ rad, $\kappa = 1.06$) and for poor responders ($\mu: -0.36$ rad, $\kappa = 1.15$).

network connections that might prevent seizures from recurring in the future might be during low-risk epochs when learning is more likely to occur and be maintained.

We defined the ratio of time spent in, and stimulation during, low-risk periods, specifically demarcated by days with fewer or equal numbers of repetitive detections known as ‘long episodes’

when compared to the average detection counts from the prior week. We found that quantification of the ratio of low-risk time and stimulation episodes were predictive of seizure reduction within the first 90 days of stimulation (Fig. 3A and B). Further, patients with a greater excess of high-risk stimulation episodes per seizure than chance exhibited worse outcomes (Fig. 3E), an indication that low-risk stimulation likely plays an important role in therapy in addition to high-risk stimulation.

Additional evidence that stimulation during periods of reduced epileptiform activity may be important for inducing long-term changes in brain dynamics that suppress seizures is the comparable success seen in open-loop deep brain stimulation for epilepsy. While there has not been a clinical trial directly comparing the outcomes of deep brain stimulation (DBS) for epilepsy and RNS, the outcomes from both groups are relatively comparable.²⁶ According to a systematic review of hippocampal DBS, a close parallel to the frequent mesial temporal locations of responsive stimulation leads, the mean seizure reduction was 67.8%.²⁷ For generalized epilepsies using DBS, anterior thalamic nucleus and centromedian thalamic nucleus lead locations had a 60.8% and 73.4% mean seizure reduction.²⁷ In a comparison of patients with temporal lobe epilepsy with DBS and the RNS system, median seizure reduction was 58% after 12–15 months for 26 anterior thalamic DBS patients and 70% for 32 patients with temporal lobe RNS.²⁸ DBS for epilepsy does not produce a continuous train of pulses as typical for movement disorders, but rather follows a 1-min ‘on’ cycle and 5-min ‘off’ cycle. Given that stimulation timing is non-specific to seizure state in DBS, stimulation during low-risk states is guaranteed (represented by the blue line in Fig. 3D).

Recent work has shown that patients experience multiscale seizure cycles that may be circadian or multidien.^{12–14} We were able to reproduce findings from Baud *et al.*¹² and saw similar late evening, early morning and afternoon peaks in detections on a circadian cycle in our patient cohort (Fig. 4A and C). Moreover, we found in Fig. 4B that a larger circadian phase-locking value was correlated with improved seizure reduction, which may enable more ‘low-risk’ periods daily due to stronger clustering of detections in smaller windows of the day.

We showed that the periodograms between super-responders and intermediate/poor responders diverged over the course of therapy (Fig. 5C and D), with super-responder patients demonstrating increased strength in circadian or faster rhythms compared to intermediate/poor responders, who had stronger multidien, slower rhythms. This shift may serve as preliminary evidence that detections in super-responder patients may exhibit daily rhythms that more closely resemble rhythms one might expect in healthy subjects with no history of seizures. Finally, we observed significant differences in the distributions of phase of long episodes and stimulation episodes between super-responders and poor/intermediate responders (Fig. 5E). Specifically, across all periods spanning 3 h to 45 days, intermediate and poor responders had stimulation highly entrained to long episodes. In contrast, super-responders experienced more instances of stimulation out of phase with long episodes, which supported our hypothesis that low-risk stimulation may play a contributing role in patient improvement through neuromodulation therapy.

While the precise mechanism leading to long-term seizure reduction is still debated, new evidence is emerging that there exists an increase in inward interictal inhibition from brain regions not involved in ictogenesis onto the seizure onset zones during rest and single-pulse stimulation.²⁹ This supports prior hypotheses that stimulation might be inducing changes that disrupt the core

synchronization of the epileptogenic zone.³⁰ Taken together, we postulate that responsive neural stimulation may be acting to de-segregate the seizure onset zone (SOZ) from other brain regions by increasing the strength of outward connectivity from the SOZ to normal levels through neuromodulation-induced plasticity during epochs with reduced epileptic activity. Additionally, in patients with better outcomes, the inhibitory-excitatory balance changes favouring a decrease in low frequency power and increase in high frequency power.^{31,32} This shift in the inhibitory-excitatory balance, even when a patient is immediately seizure-free after resection surgery, changes in electrographic recordings are slow to manifest.³² This slow change over time aligns with the methodically slow improvement observed in RNS system patients over long periods of therapy.³

The findings from this work compliments existing literature that demonstrate induced network changes are critical to successful outcomes in RNS therapy. Prior work has uncovered that certain electrographic features change in super-responder patients over the course of therapy, including altered frequency dynamics of seizures, changes in ictal duration and spontaneous ictal inhibition,⁵ as well as changes in the phase-locking value across different frequency bands over therapy.⁶ Until our study, there has not yet been a mechanistic explanation as to why there might be a disparity across functional changes across patient groups. This work uniquely proposes a hypothesis that these functional changes are driven during periods of reduced epileptiform risk and may ultimately guide how programming of closed-loop stimulation may be targeted in the future to accelerate network changes.

Future directions

Based on this evidence, it appears that the ratio of time in low-risk states may be an early predictor of therapeutic outcome. While the calculations of low-risk state are related to counted detections saved from the NeuroPace RNS system, it may be possible to determine low-risk time prior to the implant of the device using intracranial EEG. This may be done using similar detection settings to the device's line length detector or band pass range thresholding and similarly defining long episodes from prolonged detections. While our paper focused on the timing of stimulation, previous studies from our group found that patient-specific structural connections are predictive of clinical outcomes.³³ It may be possible to combine both the structural and temporal aspects of stimulation for improved predictability. The amount of time spent in low-risk states could also potentially be used as a surrogate of patient improvement where reporting of seizure frequency can be imperfect. As previously reported, the ratio of time spent in low-risk states in Fig. 3C steadily increased over time in intermediate/poor responders, which parallels the slow but steady improvement over time reported in RNS system patients in long-term follow-up studies.³ Further, perhaps parameters of closed-loop devices could be adjusted to increase targeting of low-risk states to facilitate network changes. Additionally, if improvements in neuromodulation therapy over time are due to functional changes driven by neuromodulation-induced plasticity, stimulation may be programmed to facilitate these long-term improvements to occur earlier.

Limitations

In this paper, we put forward a potential mechanism for successful RNS for epilepsy with an emphasis on neuromodulation-induced

plasticity being responsible for driving network changes necessary to prevent future seizures. We were limited in this study by using retrospective data, and this study does not show causation. Patients who had better outcomes may simply be in more low-risk epochs because they have fewer seizures early on, perhaps due to a more pronounced micro-lesion effect following implantation.³⁴ Similarly, it is possible that the patterns of interictal events are fundamentally different across outcome groups, which resulted in a higher prevalence of stimulation episodes during low-risk periods in super-responders. Despite this, a divergence in low-risk time between super-responders and intermediate/poor responders occurred early in therapy (first 90 days) with steady improvement in intermediate/poor responders over time. As such, this metric may be useful in future work to objectively quantify improvement over time. Further, it would benefit our findings if it were possible to quantify the ratio of time in high- and low-risk states prior to implant of the RNS system and potentially use that as a predictor for seizure outcome prior to any surgery.

Another limitation is the lack of full characterization of detected events by the closed-loop system. Whether detections are interictal discharges, trains of discharges or spurious detections are not adjudicated at the individual event level. Despite this, we found correlation between baseline long episode counts and seizures, and papers using similar methodology have found similar agreement with detections of interictal epileptiform activity such as spike-waves, rhythmic alpha/beta and low voltage fast activity.¹² Yet, these trends remain predictive, regardless of their precise characterization. Finally, patients in this cohort remained on anti-epileptic medications concurrent with the RNS system and we did not study whether adherence to medication coupled with the RNS system could lead to better outcomes. It is also feasible that certain drugs may put patients in low-risk periods more often and thus facilitate neuromodulation-induced plasticity. Despite these limitations, we believe our results support further exploration of stimulation during low-risk states as a means to generate long-term functional changes seen in patients with excellent outcomes from neuromodulation.

Data availability

All de-identified data are available upon request to the corresponding author.

Funding

National Institutes of Health, National Institute for Neurological Disorders and Stroke F32NS114322 (D.N.A.), National Institutes of Health, National Institute for Neurological Disorders and Stroke K23NS114178 (J.D.R.).

Competing interests

J.D.R. has served as a consultant for Medtronic, NeuroPace, and Corlieve Therapeutics. C.R.B. has served as a consultant for NeuraModix and Abbott and holds intellectual property related to neuromodulation therapy.

Supplementary material

Supplementary material is available at *Brain* online.

References

1. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. *Neurology*. 2015;84(8):810-817. doi:10.1212/WNL.0000000000001280
2. Morrell MJ. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. *Neurology*. 2011;77:1295-1304.
3. Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. *Neurology*. 2020;95:e1244-e1256.
4. Rønborg SN, Esteller R, Tchong TK, et al. Acute effects of brain-responsive neurostimulation in drug-resistant partial onset epilepsy. *Clin Neurophysiol*. 2021;132:1209-1220.
5. Kokkinos V, Sisterson ND, Wozny TA, Richardson RM. Association of closed-loop brain stimulation neurophysiological features with seizure control among patients with focal epilepsy. *JAMA Neurol*. 2019;76:800-808.
6. Khambhati AN, Shafi A, Rao VR, Chang EF. Long-term brain network reorganization predicts responsive neurostimulation outcomes for focal epilepsy. *Sci Transl Med*. 2021;13:eabf6588.
7. Beck H, Goussakov I V, Lie A, Helmstaedter C, Elger CE. Synaptic plasticity in the human dentate gyrus. *Thus. J Neurosci*. 1996;20:7080-7086.
8. Abegg MH, Savic N, Ehrenguber MU, McKinney RA, Gähwiler BH. Epileptiform activity in rat hippocampus strengthens excitatory synapses. *J Physiol*. 2004;554:439-448.
9. Naik AA, Sun H, Williams CL, Weller DS, Julius Zhu J, Kapur J. Mechanism of seizure-induced retrograde amnesia. *Prog Neurobiol*. 2021;200:101984.
10. Lesser RP, Kim S, Beyderman L, et al. Brief bursts of pulse stimulation terminate afterdischarges caused by cortical stimulation. *Neurology*. 1999;53:2073-2081.
11. Chiang S, Khambhati AN, Wang ET, Vannucci M, Chang EF, Rao VR. Evidence of state-dependence in the effectiveness of responsive neurostimulation for seizure modulation. *Brain Stimul*. 2021;14:366-375.
12. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. *Nat Commun*. 2018;9:88.
13. Gregg NM, Sladky V, Nejedly P, et al. Thalamic deep brain stimulation modulates cycles of seizure risk in epilepsy. *Sci Rep*. 2021;11:24250.
14. Leguia MG, Andrzejak RG, Rummel C, et al. Seizure cycles in focal epilepsy supplemental content CME quiz at jamacmelookup.com. *JAMA Neurol*. 2021;78:454-463.
15. Berens P. Circstat: A MATLAB toolbox for circular statistics. *J Stat Softw*. 2009;31:1-21.
16. Louie KH, Lu C, Abdallah T, et al. Gait phase triggered deep brain stimulation in Parkinson's disease. *Brain Stimul*. 2021;14:420-422.
17. Gilron R, Little S, Perrone R, et al. Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease. *Nat Biotechnol*. 2021;39:1078-1085.
18. Cagle JN, Okun MS, Cernera S, et al. Embedded human closed-loop deep brain stimulation for Tourette syndrome: a nonrandomized controlled trial syndrome. *JAMA Neurol*. 2022;79:1064-1068.
19. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: Rewiring the brain. *Prog Neurobiol*. 2004;73:1-60.
20. Jarero-Basulto JJ, Gasca-Martínez Y, Rivera-Cervantes MC, Ureña-Guerrero ME, Fera-Velasco AI, Beas-Zarate C. Interactions between epilepsy and plasticity. *Pharmaceuticals (Basel)*. 2018;11:17.

21. Bains JS, Longacher JM, Staley KJ. Reciprocal interactions between CA3 network activity and strength of recurrent collateral synapses. *Nat Neurosci*. 1999;2:720-726.
22. Leeman-Markowski B, Hardstone R, Lohnas L, et al. Effects of hippocampal interictal discharge timing, duration, and spatial extent on list learning. *Epilepsy Behav*. 2021;123:108209.
23. Camarillo-Rodriguez L, Leenen I, Waldman Z, et al. Temporal lobe interictal spikes disrupt encoding and retrieval of verbal memory: A subregion analysis. *Epilepsia*. 2022;63:2325-2337.
24. Reed CM, Mosher CP, Chandravadia N, Chung JM, Mamelak AN, Rutishauser U. Extent of single-neuron activity modulation by hippocampal interictal discharges predicts declarative memory disruption in humans. *J Neurosci*. 2020;40:682-693.
25. Liu S, Parvizi J. Cognitive refractory state caused by spontaneous epileptic high-frequency oscillations in the human brain. *Sci Transl Med*. 2019;11:eaax7830.
26. Klinger N, Mittal S. Deep brain stimulation for seizure control in drug-resistant epilepsy. *Neurosurg Focus*. 2018;45:E4.
27. Vetkas A, Fomenko A, Germann J, et al. Deep brain stimulation targets in epilepsy: Systematic review and meta-analysis of anterior and centromedian thalamic nuclei and hippocampus. *Epilepsia*. 2022;63:513-524.
28. Yang JC, Bullinger KL, Dickey AS, et al. Anterior nucleus of the thalamus deep brain stimulation vs temporal lobe responsive neurostimulation for temporal lobe epilepsy. *Epilepsia*. 2022; 63:2290-2300.
29. Johnson GW, Doss DJ, Morgan VL, et al. The interictal suppression hypothesis in focal epilepsy: Network-level supporting evidence. *Brain*. 2023;146:2828-2845.
30. Sistrerson ND, Wozny TA, Kokkinos V, Constantino A, Richardson RM. Closed-Loop brain stimulation for drug-resistant epilepsy: Towards an evidence-based approach to personalized medicine. *Neurotherapeutics*. 2019;16:119-127.
31. Lundstrom BN, Van Gompel J, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. *Brain Commun*. 2019; 1:fcz010.
32. Kundu B, Charlebois CM, Anderson DN, Peters A, Rolston JD. Chronic intracranial recordings after resection for epilepsy reveal a “running down” of epileptiform activity. *Epilepsia*. 2023; 64:135-142.
33. Charlebois CM, Anderson DN, Johnson KA, et al. Patient-specific structural connectivity informs outcomes of responsive neurostimulation for temporal lobe epilepsy. *Epilepsia*. 2022; 63:2037-2055.
34. Oommen J, Morrell MJ, Fisher R. Experimental electrical stimulation therapy for epilepsy. *Curr Treat Options Neurol*. 2005;7: 261-271.